Showing 1–12 of 12 · Surgical & theatre systems
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 adjusted EBITA SEK 4.88bn, a 14.0% adjusted margin; organic growth 4.9%.
Band uses the adjusted margin; reported net sales and profit not yet captured.
FY2025 revenue $10.06bn (+20.5%); operating margin 29.3%; net income $2.86bn.
No debt; $9.03bn cash and investments.
Parent Johnson & Johnson (JNJ) group FY2025 revenue $94.19bn (+6.0%); pre-tax margin 34.6%; net income $26.80bn.
MedTech segment sales $33.79bn (+6.1%).
FY2025 revenue ¥1.01tn (+1.3%); operating margin 9.6%; net income ¥68.2bn.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.
Net debt $2.76bn including leases.
FY2025 revenue $25.12bn (+11.2%); operating margin 19.5%; net income $3.25bn.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $8.23bn (+7.2%); operating margin 13.3%; net income $705.1m.
Cash $591.9m; debt $7.52bn.